Table of Contents

• Overview of Clinical Research
• Understanding the Imaging Agent
• Trial Design and Objectives
• Target Patient Population
• Study Methodology and Administration
• Primary Outcomes and Measurements
• Clinical Significance

Overview of Clinical Research

Clinical trials are currently investigating [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2, also known as [68Ga]NODAGA-E[c(RGDyK)]2, as a specialized imaging agent for patients with heart disease^[1]. This research represents an important advancement in cardiac imaging technology, focusing on the ability to visualize and measure new blood vessel formation in the heart muscle.

The primary research initiative is an authorized Phase 2 interventional study that aims to evaluate how effectively this radioactive tracer can detect angiogenesis in patients with chronic ischemic heart disease^[1]. Angiogenesis refers to the body’s natural process of creating new blood vessels, which is particularly important in heart disease where blood flow to the heart muscle is compromised.

The trial is designed to assess changes in angiogenesis patterns at two critical time points: before patients undergo coronary revascularization procedures and after these procedures are completed^[1]. This comparative approach allows researchers to understand how the heart’s blood vessel network responds to treatment interventions.

Understanding the Imaging Agent

[68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is a radioactive compound used specifically for PET imaging (Positron Emission Tomography)^[1]. The substance contains gallium-68, a radioactive isotope that emits signals detectable by PET scanners, allowing doctors to create detailed images of internal body structures and processes.

The compound is also referred to by its shortened name, [68Ga]NODAGA-E[c(RGDyK)]2, in clinical documentation^[1]. The “RGD” portion of the name refers to a specific sequence of amino acids (arginine-glycine-aspartic acid) that has the ability to bind to proteins involved in new blood vessel formation. This binding property makes the substance particularly useful for imaging angiogenesis.

When injected into patients, the substance travels through the bloodstream and accumulates in areas where new blood vessels are forming^[1]. The radioactive component allows these areas to be visualized on PET scans as regions of increased uptake, providing doctors with a map of where angiogenesis is occurring in the heart muscle.

Trial Design and Objectives

The clinical trial investigating [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is structured as a Phase 2 interventional study with authorization status^[1]. Phase 2 trials are designed to evaluate how well a diagnostic tool or treatment works in a larger group of patients while continuing to monitor safety.

The study has a planned enrollment of 42 participants, which provides a sufficient sample size to evaluate the imaging capabilities of the substance in the target population^[1]. This enrollment number is typical for Phase 2 imaging studies, balancing the need for meaningful data with practical considerations of patient recruitment and study resources.

The trial’s primary objective is clearly defined: to characterize the difference in myocardial angiogenesis measured with RGD-PET uptake before and after coronary revascularization^[1]. This objective addresses a critical question in cardiac care: how does the heart’s ability to form new blood vessels change after procedures designed to restore blood flow.

The study design follows a longitudinal approach, meaning patients undergo imaging at multiple time points throughout their treatment journey^[1]. This allows researchers to track changes in angiogenesis within the same patients, providing more reliable data than comparing different groups of patients.

Target Patient Population

The clinical trial specifically targets patients diagnosed with chronic ischemic heart disease^[1]. This condition occurs when the coronary arteries, which supply blood to the heart muscle, become narrowed or blocked over time, typically due to the buildup of fatty deposits called plaques.

Patients with chronic ischemic heart disease often experience symptoms such as chest pain (angina), shortness of breath, and reduced exercise tolerance^[1]. The chronic nature of the condition means these patients have had reduced blood flow to their heart muscle for an extended period, which can trigger the body’s natural angiogenesis response as it attempts to create new pathways for blood flow.

The study specifically enrolls patients who are scheduled to undergo coronary revascularization procedures^[1]. These procedures include interventions such as:

• Percutaneous coronary intervention (PCI): A procedure where blocked arteries are opened using a balloon and often a stent (a small mesh tube) to keep the artery open
• Coronary artery bypass grafting (CABG): Surgery where healthy blood vessels from other parts of the body are used to create new pathways around blocked coronary arteries

By focusing on patients undergoing these procedures, the trial can evaluate how revascularization affects the heart’s natural angiogenesis processes and whether the imaging agent can effectively capture these changes^[1].

Study Methodology and Administration

In the clinical trial, [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is administered to participants through injection^[1]. The standardized dose used in the study is 300 megabecquerels (MBq), which represents the amount of radioactivity in the injected substance.

The administration process follows a specific protocol^[1]:

1. Pre-imaging preparation: Patients are prepared for the PET scan according to standard imaging protocols
2. Injection: The 300 MBq dose of [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is administered intravenously
3. Distribution period: After injection, time is allowed for the substance to circulate through the bloodstream and accumulate in areas of angiogenesis
4. PET imaging: Patients undergo PET scanning to capture images of the radioactive tracer uptake in the heart muscle

The imaging technique used is referred to as RGD-PET, which specifically refers to PET imaging using substances containing the RGD peptide sequence^[1]. This specialized imaging approach allows for targeted visualization of angiogenesis markers in the heart tissue.

Patients undergo this imaging procedure at two distinct time points: once before their scheduled coronary revascularization procedure and again afterward^[1]. This before-and-after approach enables researchers to directly compare angiogenesis patterns and measure any changes resulting from the revascularization treatment.

Primary Outcomes and Measurements

The primary outcome measure of the trial focuses on characterizing the difference in myocardial angiogenesis as measured by RGD-PET uptake before and after coronary revascularization^[1]. This outcome is quantitative, meaning researchers will use numerical measurements to assess changes in angiogenesis.

The measurement of uptake refers to how much of the radioactive tracer accumulates in the heart muscle tissue^[1]. Areas with active angiogenesis show higher uptake of the substance because the RGD component binds to proteins expressed during new blood vessel formation. These areas appear as brighter regions on PET images.

Researchers will analyze several aspects of the imaging data:

• Baseline angiogenesis: The pattern and intensity of tracer uptake before revascularization, showing where the heart is attempting to form new blood vessels in response to chronic ischemia
• Post-revascularization changes: How the angiogenesis pattern changes after blood flow is restored through revascularization procedures
• Regional differences: Whether certain areas of the heart muscle show more pronounced changes in angiogenesis than others
• Quantitative measurements: Specific numerical values representing the amount of tracer uptake in different regions of the heart

By characterizing these differences, the trial aims to provide detailed information about how the heart’s natural healing processes respond to medical interventions^[1]. This information could potentially help doctors better understand treatment effectiveness and predict patient outcomes.

Clinical Significance

The investigation of [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 for imaging angiogenesis in chronic ischemic heart disease represents an important area of cardiovascular research^[1]. Understanding how new blood vessels form in response to ischemia and treatment could have several clinical implications.

Currently, doctors assess the success of coronary revascularization procedures primarily by evaluating blood flow restoration and symptom improvement^[1]. However, the ability to visualize and measure angiogenesis could provide additional information about the heart’s biological response to treatment. This could help identify patients who are healing well versus those who may need additional interventions.

The trial’s focus on characterizing angiogenesis patterns before and after revascularization could help answer important clinical questions^[1]:

• Does successful revascularization enhance the heart’s natural angiogenesis processes?
• Are there patients in whom angiogenesis continues despite restored blood flow?
• Can imaging predict which patients will have better long-term outcomes?
• Does the degree of angiogenesis correlate with symptom improvement?

For patients with chronic ischemic heart disease, the development of effective imaging techniques for angiogenesis could lead to more personalized treatment approaches^[1]. If doctors can visualize how individual patients’ hearts are forming new blood vessels, they may be able to tailor treatments more effectively.

The use of PET imaging with [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 offers advantages over other imaging methods because it provides functional information about biological processes rather than just anatomical pictures^[1]. This functional imaging capability could complement existing diagnostic tools and provide a more complete picture of heart health.

As the trial progresses through Phase 2, the data collected will help determine whether this imaging approach should advance to larger Phase 3 studies^[1]. Successful completion of this research could eventually lead to the availability of RGD-PET imaging as a clinical tool for managing patients with chronic ischemic heart disease, potentially improving treatment planning and outcome prediction.